Search research articles
Contact Us
Filters
Showing results (41-50 of 49) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 49 results.
Clinical Journal of the American Society of Nephrology : CJASN
|
March 22, 2022
Multifaceted Intervention to Increase the Use of Home Dialysis: A Cluster Randomized Controlled Trial
Braden J Manns, Amit X Garg, Manish M Sood, et al.
American Journal of Preventive Medicine
|
October 23, 2021
Association of Membership at a Medical Fitness Facility With Adverse Health Outcomes
Ranveer Brar, Alan Katz, Thomas Ferguson, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
September 25, 2025
Risk of Progression and Costs of Care for Patients with Type 2 Diabetes and Chronic Kidney Disease
Navdeep Tangri, Rakesh Singh, Keith A Betts, et al.
Clinical Kidney Journal
|
April 23, 2024
Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY population
Navdeep Tangri, Thomas Ferguson, Silvia J Leon, et al.
The Lancet. Oncology
|
July 14, 2023
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial
Laurence Albiges, Howard Gurney, Vagif Atduev, et al.
European Urology
|
July 24, 2025
First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial
Martin H Voss, Howard Gurney, Vagif Atduev, et al.
The Oncologist
|
August 17, 2023
Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma
Toni K Choueiri, Piotr Tomczak, Se Hoon Park, et al.
The Lancet. Oncology
|
September 2, 2022
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Thomas Powles, Piotr Tomczak, Se Hoon Park, et al.
The New England Journal of Medicine
|
August 18, 2021
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
Toni K Choueiri, Piotr Tomczak, Se Hoon Park, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 49) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 49 results.
Clinical Journal of the American Society of Nephrology : CJASN
|
March 22, 2022
Multifaceted Intervention to Increase the Use of Home Dialysis: A Cluster Randomized Controlled Trial
Braden J Manns, Amit X Garg, Manish M Sood, et al.
American Journal of Preventive Medicine
|
October 23, 2021
Association of Membership at a Medical Fitness Facility With Adverse Health Outcomes
Ranveer Brar, Alan Katz, Thomas Ferguson, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
September 25, 2025
Risk of Progression and Costs of Care for Patients with Type 2 Diabetes and Chronic Kidney Disease
Navdeep Tangri, Rakesh Singh, Keith A Betts, et al.
Clinical Kidney Journal
|
April 23, 2024
Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY population
Navdeep Tangri, Thomas Ferguson, Silvia J Leon, et al.
The Lancet. Oncology
|
July 14, 2023
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial
Laurence Albiges, Howard Gurney, Vagif Atduev, et al.
European Urology
|
July 24, 2025
First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial
Martin H Voss, Howard Gurney, Vagif Atduev, et al.
The Oncologist
|
August 17, 2023
Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma
Toni K Choueiri, Piotr Tomczak, Se Hoon Park, et al.
The Lancet. Oncology
|
September 2, 2022
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Thomas Powles, Piotr Tomczak, Se Hoon Park, et al.
The New England Journal of Medicine
|
August 18, 2021
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
Toni K Choueiri, Piotr Tomczak, Se Hoon Park, et al.
Page
of 5